NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, will announce financial results for the fourth quarter and full year ended December 31, 2006 after the close of U.S. financial markets on Thursday, March 8, 2007. An accompanying conference call to discuss the results will be held the same day at 5:00 pm ET; 2:00 pm PT.
